- Global Pharma News & Resources

Global Checkpoint Inhibitors Markets Through 2023: Biomarker Development, Immune Modulation, Innovative Delivery Technologies, and Future Landscape -

The "Checkpoint Inhibitors: Global Markets" report has been added to's offering.

This report on checkpoint inhibitors provides a detailed analysis of the market based on approved clinical and preclinical developmental candidates that target PD-1/PD-L1, CTLA-4, IDO-1, LAG-3, TIM-3 and CD47/SIRPa. The report analyzes the market trends, key medical needs and provides insights into recent advances in the modulation of checkpoint inhibition in the treatment of cancer through the development of fully human monoclonal antibodies, bispecific antibodies, fusion proteins and Chimeric Antigen Receptor (CAR) T cells.

The Report Includes:

  • An overview of the global market for checkpoint inhibitors
  • Analyses of global market trends, with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Discussion of the market landscape and innovative strategies, and the areas of unmet medical needs
  • Information on the biomarker development, immune modulation, innovative delivery technologies, and the future landscape
  • Market analysis for CP inhibitors, including PD-1/PD-L1 agents, CTLA-4 agents, TIM-3 agents, LAG-3 agents, IDO-1 agents, and SIRPa agents
  • Comprehensive company profiles of major players in the industry, including Agenus, Inc., BeiGene, BIOCAD, Forty Seven, Inc., Seattle Genetics, Inc., Shanghai Cell Therapy, Tesaro, Inc. and Xencor

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary And Highlights

Chapter 3 Immuno-Oncology Market And Checkpoint Market Statistics

Chapter 4 PD-1/PD-L1 Agents

Chapter 5 CTLA-4

Chapter 6 IDO-1

Chapter 7 LAG-3

Chapter 8 TIM-1,3

Chapter 9 CD47/Sirpa

Chapter 10 Company Profiles

Chapter 11 Appendix A: List Of Abbreviations

Chapter 12 Appendix B: Glossary Of Terms

Chapter 13 Appendix C: Sources

Companies Mentioned

  • Agenus Inc.
  • ALX Oncology
  • Anaptys Bio
  • Beigene
  • Biocad
  • Crescendo Biologics Ltd.
  • Cstone Pharmaceuticals
  • F-Star Biotechnology
  • Forty Seven, Inc.
  • Immutep, Ltd.
  • Inhibrx
  • Macrogenics, Inc.
  • OSE Immunotherapeutic
  • Regeneron Pharmaceuticals, Inc.
  • Seattle Genetics, Inc.
  • Shanghai Cell Therapy
  • Sorrento Therapeutics, Inc.
  • Surface Oncology
  • Symphogen A/S
  • Tesaro, Inc.
  • Trillium Therapeutics
  • Xencor

For more information about this report visit

View source version on

Editor Details

Last Updated: 23-Oct-2018